Retention of tin ethyl etiopurpurin (SnET2) by atheromatous plaques: studies in vitro and in vivo rabbit

Restenosis remains the greatest limitation to the success of conventional and newer forms of angioplasty for the treatment of coronary artery disease. Since the armamentarium available to the clinician is presently limited to mechanical forms of intervention, invariably causing an acute response to injury, a pharmacologic alternative is sought. Photodynamic therapy has the potential to provide a combined drug/device therapy to significantly reduce the rate of restenosis through selective cytolysis and cytostasis. In this study Tin Ethyl Etiopurpurin, a second generation photosensitizer, demonstrated selective retention in catheter induced atheromatous plaques in a New Zealand White rabbit model in vitro and in vivo.

[1]  J. Spears,et al.  Uptake of hematoporphyrin derivative by atheromatous plaques: studies in human in vitro and rabbit in vivo. , 1986, Journal of the American College of Cardiology.

[2]  R Linsker,et al.  Laser-induced fluorescence detection of atherosclerotic plaque with hematoporphyrin derivative used as an exogenous probe. , 1988, Journal of vascular surgery.

[3]  Y. Hsiang,et al.  Assessing Photofrin® uptake in atherosclerosis with a fluorescent probe: Comparison with photography and tissue measurements , 1993, Lasers in surgery and medicine.

[4]  V. Fuster,et al.  Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. , 1990, Journal of the American College of Cardiology.

[5]  P. Dartsch,et al.  Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: implications for photodynamic therapy of vascular stenoses. , 1990, Journal of the American College of Cardiology.

[6]  R. Wilensky,et al.  8‐Methoxypsoralen and Longwave Ultraviolet Irradiation Are a Novel Antiproliferative Combination for Vascular Smooth Muscle , 1993, Circulation.

[7]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[8]  S Paulin,et al.  Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative. , 1983, The Journal of clinical investigation.

[9]  E D Sternberg,et al.  Second generation photodynamic agents: a review. , 1993, Journal of clinical laser medicine & surgery.

[10]  Steven H. Selman,et al.  Tin (IV) Etiopurpurin Dichloride: An Alternative To DHE? , 1988, Other Conferences.

[11]  T J Flotte,et al.  Chloroaluminum sulfonated phthalocyanine partitioning in normal and intimal hyperplastic artery in the rat. Implications for photodynamic therapy. , 1993, The American journal of pathology.

[12]  Y. Hsiang,et al.  DETERMINING THE OPTIMAL DOSE OF PHOTOFRIN® IN MINISWINE ATHEROSCLEROTIC PLAQUE , 1993, Photochemistry and photobiology.

[13]  R Berguer,et al.  Determinants of porphyrin fluorescence emission spectra of atheromatous plaques. , 1988, Atherosclerosis.